Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed to Collaborate with PPD on Clinical Development

publication date: Aug 27, 2019

Harbour BioMed, a Boston, Rotterdam and Shanghai biopharma, formed a collaboration with PPD, a global clinical CRO. to develop HBM's novel portfolio of oncology and immunology assets. The two companies recently completed a submission in Australia for an oncology immunotherapy that targets solid tumors, part of the requirements for starting Phase I trials. Founded in 2016, HBM includes a Dutch drug antibody discovery unit. Its portfolio includes five in-licensed candidates, a set of internally discovery molecules, and co-discovery/development collaborations with academic and biopharma entities. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital